Friday, 16 October 2026European Markets

AIRTHINGS Stock Over 18% Down Today

Loading stream...

(VIANEWS) - Shares of AIRTHINGS (Oslo Børs All-share Index_GI: AIRX.OL) dropped by a staggering 18.07% to 3.11 kr at 16:25 EST on Friday, after two consecutive sessions in a row of gains. Oslo Børs All-share Index_GI is jumping 0.34% to 1,417.88 kr, after three consecutive sessions in a row of losses. This seems, so far, a somewhat up trend trading session today.

About AIRTHINGS

Airthings ASA, together with its subsidiaries, engages in the manufacture and sale of air quality sensors and hardware-enabled software products for air quality, radon measurement, and energy efficiency solutions worldwide. The company operates through three segments: Consumer, Business, and Professional segments. It offers digital radon detectors, as well as smart indoor air quality monitors and solutions for professionals, homes, schools, offices, and other commercial buildings. The company provides its products under the View Plus, Wave Plus, Wave Radon, Wave Mini, House Kit, Hub, Corentium Home, Plus, and Pro brands. It also serves homeowners, businesses, and professionals. The company was incorporated in 2008 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, AIRTHINGS has a trailing twelve months EPS of -0.3 kr.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, AIRTHINGS's stock is considered to be oversold (<=20).

Volatility

AIRTHINGS's last week, last month's, and last quarter's current intraday variation average was a negative 0.05%, a positive 0.33%, and a positive 1.82%.

AIRTHINGS's highest amplitude of average volatility was 1.41% (last week), 2.33% (last month), and 1.82% (last quarter).

More news about AIRTHINGS (AIRX.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com